A Short-Order Oncology Start-Up: Non-Profit Tackles Drug Shortages
This article was originally published in RPM Report
Drug shortages are a big problem in cancer, where many generic sterile injectables are both life-saving and irreplaceable. Some oncologists have decided to take control and form a manufacturer of their own.
You may also be interested in...
Non-profit probably won’t ever be significant threat to industry – but frustration with chronic shortages could prompt policy changes that are.
Both houses have introduced legislation to require manufacturers to notify FDA in advance of planned interruptions or as soon as possible when facing a shortage. Here’s a look at the details.
Omaveloxolone, Reata Pharmaceuticals’s orphan drug for treating patients with Friedreich’s ataxia, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.